Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493327 | 0.96 | EPHX2 (0.39) | EPHX2FAAHACHECCR5POLB | |
| SCHEMBL492583 | 0.94 | EPHX2 (0.40) | EPHX2FAAHACHECCR5POLB | |
| SCHEMBL492660 | 0.91 | POLB (0.37) | EPHX2FAAHACHECCR5POLB | |
| SCHEMBL494103 | 0.90 | EPHX2 (0.40) | EPHX2CCR5POLBMEN1KMT2A | |
| SCHEMBL492770 | 0.89 | FAAH (0.41) | EPHX2FAAHACHEPOLBBCHE | |
| SCHEMBL493814 | 0.88 | PTGIR (0.41) | EPHX2FAAHACHECCR5POLB | |
| SCHEMBL492702 | 0.88 | EPHX2 (0.41) | EPHX2FAAHACHECCR5BCHE | |
| SCHEMBL493126 | 0.86 | ALDH1A1 (0.39) | EPHX2CCR5POLBMEN1KMT2A | |
| SCHEMBL492870 | 0.86 | FAAH (0.38) | EPHX2FAAHACHEBCHEMEN1 | |
| SCHEMBL492760 | 0.85 | POLB (0.41) | EPHX2FAAHACHEPOLBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | EPHX2 2567/4885FAAH 6/4885ACHE 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.